Invesco Dynamic Biotechnology & Genome
ALTAR
Score™
0.0% info Recommen-
dation
AVOID
2019E    2020E
P/E
ratio
37.2x P/Sales
ratio
5.3x
P/BV
ratio
4.6x Div.
yield
0.4%


  • Description
  • Performance
  • Comps
  • premium Fundamentals
  • premium Valuation
  • premium Rating
The Invesco Dynamic Biotechnology & Genome Portfolio ETF tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.

FUND BASICS
Category US Equities
Fund Sponsor Invesco PowerShares
Website www.powershares.com
Inception date Jun 23, 2005
Assets (mns) $225
Currency USD
Expense ratio 57 bp
Distributions Quarterly

FUND STRUCTURE
Regulation Open-Ended Fund
Custodian BNY Mellon
Weighting Tiered
Index replication
Uses derivatives No
Options available Yes

SECTOR BREAKDOWN

 


CONSTITUENT BREAKDOWN
No. of constituents 30
Wgt avg mkt cap (mns) $26,786
Large cap (>$10bn) 37.0%
Mid cap ($2-10bn) 40.7%
Small cap (<$2bn) 22.3%
Developed mkts 100.0%
Emerging mkts 0.0%

TOP TEN HOLDINGS
BIOGEN IDEC INC 6.3 %
VERTEX PHARMACEUTICALS INC 5.7 %
NEUROCRINE BIOSCIENCES INC 5.7 %
CELGENE CORP 5.6 %
AMGEN INC 5.2 %
INCYTE CORP 5.2 %
GILEAD SCIENCES INC 5.0 %
ALEXION PHARMACEUTICALS INC 4.7 %
ARROWHEAD PHARMACEUTICALS, INC. 3.6 %
EMERGENT BIOSOLUTIONS INC 3.5 %
Total 50.5 %

TOP COUNTRY EXPOSURE
UNITED STATES 97.4 %
IRELAND 2.7 %









HISTORICAL PERFORMANCE info

  Custom date range Compare to  
  thru


Standardized Annual Returns (thru October 31)
Year-to-date 1 year 5 years 10 years Since Incep.
8.4% -0.4% 0.9% 13.2% 9.1%

Market Correlations
versus... Beta R-squared
S&P500 1.33 54%
MSCI EAFE 0.99 25%
MSCI Emg. Mkts. 0.78 26%

Technical Indicators
Recent close $52.99
30d moving avg. $50.69
Annualized volatility 21.9%
Short interest (ETF) 0.0%
Short interest (Underlying) 8.4%
Relative strength (RSI) 73

Liquidity measures
Avg. volume (thou.) 9
Turnover 0.2%
Bid/Ask (% of price) 0.21%
ADV underlying (mns) $3,171

Distributions


FINDING ALTERNATIVE FUNDS

Below is a list of 20 potential alternatives to the Invesco Dynamic Biotechnology & Genome ETF based on the alternatives' overlap in portfolio holdings with PBE. Consider funds with lower expense ratios and/or higher ALTAR Score™ ratings as possible alternatives.

Benchmark ticker: PBE Expense: 57 bp ALTAR Score™: 0.0%


ALTERNATIVE ETFs BASED ON OVERLAP WITH PBE
Ticker Fund
Name
Overlap1
vs PBE
(%)
Expense
ratio
(bp)
Savings
vs PBE
(bp)
ALTAR
Score™
(%)
ALTAR
vs PBE
(%)
BBP BioShares Biotech Products 42.4 79 -22 -3.7 -3.8
BBH VanEck Vectors Biotech 39.9 35 22 5.2 +5.2
IBB iShares NASDAQ Biotechnology 39.1 47 10 1.2 +1.2
FBT First Trust NYSE-ARCA Biotechnology 37.3 57 0 -0.8 -0.8
XBI SPDR S&P Biotech ETF 33.8 35 22 -4.9 -4.9
IEIH iShares Evolved U.S. Innovative Healthcare 29.2 18 39 4.7 +4.7
PJP Invesco Dynamic Pharmaceuticals 25.9 56 1 9.7 +9.7
GNOM Global X Genomics & Biotechnology 18.4 68 -11 -6.2 -6.2
SBIO ALPS Medical Breakthroughs 18.0 50 7 -6.0 -6.0
LNGR Global X Longevity Thematic 16.2 50 7 3.7 +3.6
FTVA Aptus Fortified Value 12.2 79 -22 11.4 +11.4
XLV Health Care Select Sector SPDR 12.0 13 44 7.3 +7.3
IYH iShares US Healthcare 12.0 43 14 6.4 +6.4
QQXT First Trust NASDAQ-100 Ex-Tech 12.0 60 -3 6.0 +6.0
PSCH Invesco S&P Small Cap Health Care 11.9 29 28 2.8 +2.8
RYH Invesco S&P Equal Weight Healthcare 11.9 40 17 7.1 +7.1
FHLC Fidelity MSCI Health Care 11.7 8 49 5.9 +5.9
VHT Vanguard Health Care 11.5 10 47 5.9 +5.9
FXH First Trust Health Care Alphadex 11.0 63 -6 7.1 +7.1
BTEC Principal Healthcare Innovators Index 10.3 42 15 -4.4 -4.4

1Overlap is the percentage of holdings by weight that are identical. For example, if Fund A has a 2% position in Apple, Inc. (AAPL) and Fund B has a 5% position, their overlapping position in AAPL is 2%.

Content on this tab for subscribers only**

RESULTS & ESTIMATES

  2014 2015 2016 2017 2018 2019E 2020E
Sales per share ** ** ** ** ** ** **
Earnings per share ** ** ** ** ** ** **
Dividends per share info ** ** ** ** ** ** **
Book value per share ** ** ** ** ** ** **

 

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

Sales per share growth   **% **% **% **% **% **%
EPS growth   **% **% **% **% **% **%

OTHER FUNDAMENTAL METRICS

Long term EPS growth est. **%   Debt-to-equity **x
Asset turnover **%   Assets-to-equity **x

Return on equity

Revision activity*
*Six months ago = 100

Net margins

Compound annual growth rates

Content on this tab for subscribers only

VALUATION METRICS
  2018 2019E 2020E
Price-to-sales ** ** **
Price-to-earnings ** ** **
Price-to-cash flow ** ** **
Price-to-growth ** ** **
Price-to-book value ** ** **
Yield ** ** **

Historical valuation trends

Forward
multiple:
Invesco Dynamic Biotechnology & Genome
Relative
to:
S&P500 MSCI EAFE MSCI Emg. Mkts. Other ETF:

AVOID

Not worthwhile for most investors. A rating of AVOID is assigned to ETFs with ALTAR Scores in the lowest quintile (the bottom 20%) of their category. Often, funds in this category consist of stocks with little if any history or expectation of profitability, and as a result our fundamentally-driven analysis may not be relevant.

ALTAR Score™


Calculation of ALTAR Score™
Avg. Return on Equity 2.5 %
Divided by: Fwd. P/BV 4.2 x
Less: Expense ratio 57 bp
Equals: ALTAR Score 0.0 %
info More information on ALTAR Score™

MODERN PORTFOLIO THEORY info

CONSENSUS RECOMMENDATIONS: FUND CONSTITUENTS
COMPOSITE
RATING
1.48 CATEGORY
AVERAGE
1.55
 
The composite rating is a weighted average of analysts' consensus recommendations for individual ETF constituents, based on the following scale:

BUY = 1; OVERWEIGHT = 1.5, HOLD = 2; UNDERWEIGHT = 2.5; and SELL = 3.

Readers are cautioned that because analyst ratings tend to be inflated, the composite score may be more useful as a relative measure of sentiment between funds rather than as a stand-alone recommendation.
 

 

See RATING tab for calculation of ALTAR Score™
Risk & reward. Uses std. dev. as proxy for risk, ALTAR Score™ for return forecast.
Dividends paid by constituents to the fund. May differ from actual distributions to shareholders due to constituent changes, timing issues or other factors.
Monthly returns based on changes in price plus dividends. May differ from daily returns reported by funds. See below for standardized returns.